A cluster of blood cells

To decrease the incidence of chemotherapy-induced myelosuppression in patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen

For extensive-stage small cell lung cancer (ES-SCLC)

HEMATOLOGIC adverse REACTIONS SUMMARY

INTEGRATED SAFETY ANALYSIS OF ES-SCLC PATIENTS

  • The summary of hematologic adverse reactions based on the integrated safety dataset from across the 3 studies. The patients included are those randomized patients who received at least 1 dose of COSELA™ (trilaciclib) or placebo. The data reflects adverse reactions observed by investigators at any time during the treatment period

GRADE 3/4 Hematologic Adverse REACTIONS (Integrated Safety Dataset OF ES-SCLC PATIENTS FROM ACROSS THE 3 STUDIES)

Collapsed Preferred Term Chemotherapy Regimens with COSELA (%) N=122 Chemotherapy Regimens (%) N=118
Neutropenia 32 69
Febrile Neutropenia 3 9
Anemia 16 34
Thrombocytopenia 18 33
Leukopenia 4 17
Lymphopenia <1 <1
Collapsed Preferred Term
Chemotherapy Regimens with COSELA (%) N=122 Chemotherapy Regimens (%) N=118
Neutropenia
32 69
Febrile Neutropenia
3 9
Anemia
16 34
Thrombocytopenia
18 33
Leukopenia
4 17
Lymphopenia
<1 <1

INDICATION: COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).